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A key symptom of frontotemporal dementia (FTD) is difficulty interacting socially with
others. Social cognition problems in FTD include impaired emotion processing and theory
of mind difficulties, and whilst these have been studied extensively in sporadic FTD, few
studies have investigated them in familial FTD. Facial Emotion Recognition (FER) and Faux
Pas (FP) recognition tests were used to study social cognition within the Genetic Fronto-
temporal Dementia Initiative (GENFI), a large familial FTD cohort of C9orf72, GRN, and
MAPT mutation carriers. 627 participants undertook at least one of the tasks, and were
separated into mutation-negative healthy controls, presymptomatic mutation carriers
(split into early and late groups) and symptomatic mutation carriers. Groups were
compared using a linear regression model with bootstrapping, adjusting for age, sex,
education, and for the FP recognition test, language. Neural correlates of social cognition
deficits were explored using a voxel-based morphometry (VBM) study. All three of the
symptomatic genetic groups were impaired on both tasks with no significant difference
between them. However, prior to onset, only the late presymptomatic C9orf72 mutation
carriers on the FER test were impaired compared to the control group, with a subanalysis
showing differences particularly in fear and sadness. The VBM analysis revealed that
impaired social cognition was mainly associated with a left hemisphere predominant
network of regions involving particularly the striatum, orbitofrontal cortex and insula,
and to a lesser extent the inferomedial temporal lobe and other areas of the frontal lobe.
In conclusion, theory of mind and emotion processing abilities are impaired in familial
FTD, with early changes occurring prior to symptom onset in C9orf72 presymptomatic
mutation carriers. Future work should investigate how performance changes over time, in
order to gain a clearer insight into social cognitive impairment over the course of the
disease.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The impairment of social skills is one of the most prominent
symptoms experienced by people with frontotemporal de-
mentia (FTD) (Adenzato, Cavallo, & Enrici, 2010; Kumfor and
Piguet, 2012). The different neural processes that underlie
such skills are generally grouped together within the term
‘social cognition’ (Adolphs, 2009), and include a number of
abilities that have been shown to be impaired in FTD,
including recognition of others' emotions, and ‘theory of
mind’, the ability to understand that others have thoughts and
beliefs (Gregory et al., 2002; Lough and Hodges, 2002; Rosen
et al., 2006; Adenzato et al., 2010; Omar, Rohrer, Hailstone, &
Warren, 2011; Kumfor and Piguet, 2012).Whilst there have been a number of studies exploring
these skills in sporadic FTD, few have focused on people with
the genetic forms of FTD, characterized usually by mutations
in the progranulin (GRN), tau (MAPT) and chromosome 9 open
reading frame 72 (C9orf72) genes (Jiskoot et al., 2016, 2018,
Cheran et al., 2019). So far, these studies have been relatively
small and often focused on one (Cheran et al., 2019) or two
(Jiskoot et al., 2016, 2018) of the genetic groups, showing
change only in specific questionnaires, or when groups were
followed longitudinally.
The Genetic FTD Initiative (GENFI) is an international ge-
netic FTD cohort study, aimed at investigating early bio-
markers, including measures of cognition (Rohrer et al.,
2015). Using this cohort we therefore aimed to assess
emotion processing and theory of mind abilities in a large
c o r t e x 1 3 3 ( 2 0 2 0 ) 3 8 4e3 9 8386cohort of presymptomatic and symptomatic individuals with
mutations in the C9orf72, GRN and MAPT genes, with the
hypothesis that social cognitive deficits would become
apparent only late in the presymptomatic period or when
symptomatic.2. Methods
We report how we determined our sample size, all data ex-
clusions (if any), all inclusion/exclusion criteria, whether in-
clusion/exclusion criteria were established prior to data
analysis, all manipulations, and all measures in the study.
2.1. Participants
Participants were recruited from the fourth data freeze of the
GENFI study including sites in the UK, Canada, Sweden,
Netherlands, Belgium, Spain, Portugal, Italy and Germany. Of
the 680 participants consecutively enrolled in the study, 627
undertook at least one test of social cognition: 246 who tested
negative for the mutation within the family, and therefore
acted as the controls, 159 C9orf72 expansion carriers, 155 GRN
mutation carriers, and 67 MAPT mutation carriers (Table 1).
Mutation carriers were classified as either symptomatic or
presymptomatic based on clinician judgement. Participants
were only classified as symptomatic if the clinician judged
that symptoms were present, consistent with a diagnosis of a
degenerative disorder, and progressive in nature (Table S1).
The presymptomatic carriers were further split into those
further than five years from estimated symptom onset (based
on the mean age at onset in the family), called the ‘early’
group, and those within five years of estimated onset, called
the ‘late’ group. Diagnoses in the symptomatic group were as
follows: MAPT mutation carriers, 17 bvFTD, 1 other; GRN mu-
tation carriers, 15 bvFTD, 16 primary progressive aphasia
(PPA), 1 other; C9orf72 expansion carriers, 38 bvFTD, 10 FTD
with amyotrophic lateral sclerosis, 1 PPA, 1 progressive
supranuclear palsy and 3 other.
All participants underwent the standardized GENFI clinical
assessment including medical history, physical examination,
the Mini-Mental State Examination (MMSE), and the Clinical
Dementia Rating Scale with the National Alzheimer Coordi-
nating Centre FTLD sum of boxes score (FTLD-CDR-SOB). De-
mographics are shown in Table 1. There was a significant
difference in sex between the groups (p ¼ .018): the symp-
tomatic C9orf72 mutation carriers had a significantly higher
percentage of men than the early and late C9orf72 mutation
carriers and the control group (p ¼ .013, p ¼ .002 and p ¼ .001
respectively). There was also a significant difference in age
between the groups: all early presymptomatic mutation car-
riers were significantly younger than the control group (all
p < .001), and all late presymptomatic mutation carriers and
symptomatic mutation carriers were significantly older than
controls (all p < .001) except for the late MAPT mutation car-
riers in which no difference was observed (p ¼ .239). There
were also differences between the groups in education: the
symptomatic C9orf72 and GRN mutation carriers had signifi-
cantly lower levels of education than the control group did(p ¼ .007 and p < .001 respectively). No significant differences
in disease severity were observed between the symptomatic
genetic groups or between the late presymptomatic groups,
based on their FTLD-CDR-SOB. However, the early GRN pre-
symptomatic mutation carrier did have a significantly lower
FTLD-CDR-SOB scores than the other two early groups.
2.2. Testing of social cognition
Social cognition was tested in the GENFI cohort using the
shortened version of the Social Cognition and Emotional
Assessment, known as the mini-SEA (Bertoux et al., 2012;
Funkiewiez, Bertoux, de Souza, Levy, & Dubois, 2012) which
consists of a test of facial emotion recognition and a test of
theory of mind. It was designed specifically for people with
FTD, with initial studies showing deficits in FTD compared
with healthy controls, with people with Alzheimer's disease,
and also those with major depressive disorder (Guevara et al.,
2015; Narme, Mouras, Roussel, Devendeville, & Godefroy,
2013; Torralva, Gleichgerrcht, Torres Ardila, Roca, & Manes,
2015).
2.2.1. Experiment 1: facial emotion recognition (FER) test
The FER test is a shortened version of the standard Ekman
faces task (Ekman, Ellsworth, Friesen, Goldstein, & Krasner,
1972), with participants asked to recognise whether faces are
showing one of either six universal emotions (happiness,
surprise, anger, fear, disgust and sadness) or a neutral
expression. Participants are presented with 35 different faces
(five items for each emotion) and are required to select the
correct emotional label that matches the emotion of the face.
2.2.2. Experiment 2: faux pas (FP) recognition test
The FP recognition test contains a series of 10 short cartoon
stories describing scenarios involving social inconveniences,
known as ‘faux pas’; five of the stories contain a faux pas, the
other five do not. The task requires individuals to be able to
infer another's thoughts or beliefs. A structured questionnaire
asks how and why the social faux pas has occurred. Partici-
pants can score a maximum of 40 on this task, 10 points for
the control stories and 30 points for the faux pas stories.
2.3. Statistical analysis
In the control group, we explored the relationship of the FER
and FP recognition tests to age (Spearman rank correlation),
sex (ManneWhitney U test) and years of education (Spearman
rank correlation). For the FP recognition test, we explored the
effect of the different language versions using a linear
regression.
Scores on the two social cognitive tests (and the individual
emotion scores on the FER test) were compared between the
groups using linear regression, adjusting for age, sex and ed-
ucation (and language for the FP recognition test) with 95%
bias-corrected bootstrapped confidence intervals with 1000
repetitions (as the data was not normally distributed).
A subanalysis of the effect of phenotype was also per-
formed using the same methodology as the main analysis:
scores on the two social cognitive tests were compared
Table 1 e Demographics and scores for the Facial Emotion Recognition (FER) and Faux Pas (FP) recognition tests. N is the number of participants. Mean (standard deviation)
shown for age, education and cognitive test scores. As a slightly different number of participants attempted each test in some of the subgroups, the mean (standard deviation) sex,
age, education, MMSE and FTLD-CDR varied between those that did the FER test and those that did the FP recognition teste these are shown underneath in italics for the FP recognition
test if different.
N
(FER)/(FP)
Sex
(%
male)
Age
(years)
Education
(years)
MMSE
(/30)
FTLD-CDR
(Sum of
boxes)
FER test
score
(/35)
FER subscores by emotion (each score out of 5) FP recognition
test score (/40)Neutral Happy Surprise Disgust Fear Anger Sadness
Healthy controls 246/245 42 46.0 (12.8) 14.3 (3.5) 29.4 (1.2) .2 (.6) 28.5 (3.3) 4.8 (.5) 5.0 (.2) 4.5 (.9) 4.0 (1.0) 3.0 (1.4) 3.9 (.9) 3.5 (1.3) 35.1 (4.6)
C9orf72 Early
presymptomatic
81/81 41 41.7 (10.1) 14.8 (2.5) 29.4 (1.0) .3 (.6) 29.0 (2.9) 4.9 (.4) 5.0 (.0) 4.6 (.8) 3.8 (1.1) 3.1 (1.3) 3.9 (1.0) 3.8 (1.2) 35.0 (5.2)
Late
presymptomatic
25/24 36 56.3 (8.3)
56.5 (8.4)
13.2 (3.9)
13.1 (3.9)
28.7 (1.3)
28.7 (1.4)
.4 (.9) 26.3 (3.5) 4.8 (.5) 5.0 (.0) 4.2 (1.2) 3.6 (1.2) 2.3 (1.2) 3.7 (1.1) 2.7 (1.4) 31.9 (7.5)
Symptomatic 53/45 64
62
62.3 (8.0)
63.0 (8.0)
13.0 (3.6)
13.0 (3.7)
24.7 (4.9)
24.9 (5.2)
9.3 (5.6)
9.2 (5.3)
18.7 (6.9) 3.5 (1.8) 4.4 (1.2) 3.0 (1.6) 2.4 (1.5) 1.4 (1.3) 2.3 (1.5) 1.9 (1.5) 22.0 (9.9)
GRN Early
presymptomatic
93/93 35 41.3 (9.1) 15.0 (3.7) 29.5 (.8) .1 (.2) 29.3 (3.2) 4.9 (.4) 5.0 (.0) 4.6 (.9) 4.0 (1.0) 3.2 (1.3) 3.9 (1.0) 3.8 (1.2) 36.3 (4.3)
Late
presymptomatic
29/30 48 60.5 (6.6)
60.3 (6.5)
14.4 (3.2)
14.3 (3.1)
29.2 (1.1) .2 (.6) 28.4 (4.2) 4.8 (.7) 5.0 (.2) 4.5 (.7) 3.8 (1.2) 2.9 (1.3) 3.9 (1.2) 3.6 (1.1) 35.6 (3.7)
Symptomatic 32/22 53
41
64.2 (8.4)
62.9 (7.9)
11.6 (3.6)
11.4 (3.2)
21.8 (6.3)
21.8 (7.1)
8.6 (5.5)
8.6 (5.6)
20.0 (7.2) 3.2 (1.8) 4.4 (.9) 3.1 (1.4) 3.0 (1.7) 2.0 (1.7) 2.9 (1.4) 1.9 (1.6) 18.7 (12.2)
MAPT Early
presymptomatic
37/37 35 36.1 (8.0) 14.8 (2.7) 29.7 (.8) .3 (.6) 29.5 (3.0) 4.8 (.4) 5.0 (.0) 4.5 (.9) 4.1 (.9) 3.5 (1.6) 3.9 (1.0) 3.6 (1.3) 35.2 (4.5)
Late
presymptomatic
12/12 42 51.2 (10.2) 14.0 (3.4) 29.3 (1.0) .2 (.6) 29.4 (2.2) 4.8 (.4) 5.0 (.0) 4.8 (.5) 4.0 (1.2) 3.2 (1.2) 4.2 (.7) 3.5 (.8) 34.7 (4.5)
Symptomatic 18/12 56
50
59.8 (6.0)
59.7 (5.7)
14.6 (3.6)
15.1 (4.0)
23.2 (6.5)
25.8 (3.3)
9.0 (5.3)
8.5 (5.5)
22.3 (6.6) 4.3 (1.6) 4.8 (.5) 3.3 (1.6) 2.6 (1.7) 2.1 (1.5) 2.6 (1.6) 2.7 (1.1) 29.2 (7.0)
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c o r t e x 1 3 3 ( 2 0 2 0 ) 3 8 4e3 9 8388between the different clinical syndromes within the symp-
tomatic mutation carriers as well as with controls.
2.4. Imaging analysis
Participants underwent volumetric T1-weighted MRI using
the GENFI protocol. A variety of 3T scanners were used across
the sites: Siemens Trio, Siemens Skyra, Siemens Prisma,
Phillips and General Electric. The scan protocols were
designed at the start of the GENFI study to ensure that there
was adequatematching between the scanners and the quality
of the images. All scans were quality checked and those with
movements or artefacts were removed. Furthermore, if any
participants displayed moderate to severe vascular disease or
any other brain lesions, they were also excluded from the
analysis.
Voxel-based morphometry (VBM) was performed using
Statistical Parametric Mapping (SPM) 12 software, version
6685 (www.fil.ion.ucl.ac.uk/spm), running under Matlab
R2014a (Mathworks, USA). The T1-weighted images were
normalized and segmented into grey matter (GM), white
matter (WM) and cerebrospinal fluid (CSF) probability maps,
by using standard procedures and the fast-diffeomorphic
image registration algorithm (DARTEL) (Ashburner, 2007).
GM segmentations were affine transformed into the Montreal
Neurological Institute (MNI) space, modulated and smoothed
using a Gaussian kernel with 6 mm full-width at half
maximum before analysis. Finally, a mask was applied as re-
ported in Ridgway et al., 2009. Study-specific templates were
created based on the subjects included in the specific analysis.
At each stage, all segmentations were reviewed visually. Total
intracranial volume (TIV) was calculated using SPM (Malone
et al., 2015).
In order to explore the relationship between performance
on the tests and GM density, multiple regression models for
each genetic group were used to correlate the GM tissue
maps to the FER and FP performance in mutation carriers
(both symptomatic and presymptomatic individuals com-
bined). 319 scans were used for the FER analysis and 309
scans were used for the FP analysis (C9orf72 expansion car-
riers: FER ¼ 132, FP ¼ 128, GRN mutation carriers: FER ¼ 132,
FP ¼ 129, and MAPTmutation carriers: FER ¼ 55, FP ¼ 52) were
included in the imaging analysis. Control participants were
not included in any of the analysis. Age, sex, scanner type
and TIV were included as nuisance covariates. The Family-
Wise Error (FWE) rate for multiple comparisons correction
was set at .05. If there were no findings at that strict level of
correction, results were reviewed at an uncorrected p value of
.001.
No part of the study procedure or analyses were pre-
registered prior to the research being conducted. The condi-
tions of our ethics approval do not permit public archiving of
individual anonymised data. Readers seeking access to the
data should contact the corresponding author. Access will be
granted to named individuals in accordance with ethical
procedures governing the reuse of sensitive data, including
completion of a data sharing agreement. All stimuli and sta-
tistical code have been archived at: https://osf.io/m8yp7/?
view_only¼949ba796b549 4b7b87d37766adf840bf.3. Results
3.1. Experiment 1: facial emotion recognition (FER) test
3.1.1. Healthy controls
FER test score was not significantly correlated with either age
(rho ¼ .12, p ¼ .063) (Table S2) or education (rho ¼ .13,
p ¼ .051) (Table S3) within the controls. However, there was a
significant effect of sex (p ¼ .031): mean (standard deviation)
score overall in controls was 28.5 (3.3), with a higher score of
29.1 (3.1) in females (n ¼ 143), compared with 28.2 (3.2) in
males (n ¼ 103).
Overall, controls scored between 19 and 34 out of a total
possible score of 35, with cumulative frequency shown in
Table S4. A cut-off score below the 5th percentile is commonly
considered to be abnormal: for the FER test a score of below 23
would therefore be considered outside the normal range, with
a score of 23 considered borderline abnormal.
3.1.2. Mutation carriers
All of the three symptomatic mutation carrier groups scored
significantly lower on the FER test compared with controls
(Table 1, Table S4, Fig. 1): C9orf72 mean 18.7 (standard devia-
tion 6.9), GRN 20.0 (7.2) andMAPT 22.3 (6.6), with no significant
difference between the disease groups.
Within each genetic group, scores were significantly lower
in the symptomatic group compared with both the early and
late presymptomatic groups (Table 1, Table S5, Fig. 1).
The C9orf72 late presymptomatic group performed signifi-
cantly lower than both the C9orf72 early presymptomatic
group and the controls (Table 1, Table S5, Fig. 1): late pre-
symptomatic group 26.3 (3.5), early presymptomatic group
29.0 (2.9). No significant differences were seen between the
other presymptomatic groups and controls.
3.1.3. Phenotypic analysis
All phenotypic groups [bvFTD (19.6 {6.3}), PPA (22.0 {6.4}) and
an FTD-ALS/ALS group (18.4 {8.1})] were significantly impaired
on the FER test compared with controls, with no significant
differences between any of the clinical syndromes (Table S6
and Table S7).
3.1.4. Imaging analysis
In C9orf72 mutation carriers, FER test score was positively
associated with bilateral insula involvement, as well as atro-
phy in the left frontal lobe (middle frontal gyrus and orbito-
frontal cortex), left basal ganglia (putamen and caudate) and
right amygdala (Table S8, Fig. 2).
For the GRNmutation carriers, performance was positively
correlated with a left hemisphere predominant network of
areas involving the insula, frontal lobe, inferomedial temporal
lobe, cingulate, basal ganglia (putamen and caudate) and
thalamus (Table S8, Fig. 2).
In the MAPT mutation group FER test score positively
correlatedwith two small clusters, one in the left basal ganglia
and one in the left orbitofrontal cortex when correcting for
multiple comparisons. At an uncorrected p value of <.001,
there was also an association with the left insula and
Fig. 1 e Facial Emotion Recognition test scores in each group. Significant differences from controls and within each genetic
group are starred. Differences across genetic groups are not shown.
Fig. 2 e Neural correlates of performance on the Facial Emotion Recognition test. Results for C9orf72 and GRN groups are
shown at p < .05, corrected for Family Wise Error whilst the results for the MAPT group are shown at p < .001 uncorrected
(with the regions circled that are significant at p < .05 corrected for FamilyWise Error). Results are shown on a study-specific
T1-weighted MRI template in MNI space. Colour bars represent T-values.
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c o r t e x 1 3 3 ( 2 0 2 0 ) 3 8 4e3 9 8390inferomedial temporal lobe aswell as bilateral superior frontal
and orbitofrontal regions (Table S8, Fig. 2).
3.1.5. Subanalysis of performance on individual emotions
Identification of negative emotions (fear, anger, sadness and
disgust) was in general worse than the recognition of positive
ones (happiness and surprise) in each of the groups (including
controls).
In almost all of the emotions, the symptomatic groups
scored worse than controls (Table 1, Fig. 3). Only in the
symptomatic MAPT mutation group for happiness and fear
was there no significant difference.
In the presymptomatic groups, the C9orf72 late presymp-
tomatic group scored significantly lower than controls on both
fear and sadness, but not on the other emotions (Fig. 3). No
other significant differences were seen in the presymptomatic
groups compared with controls.
3.2. Experiment 2: faux pas (FP) recognition test
3.2.1. Healthy controls
As the FP recognition test was performed in eight different
language versions, we initially compared the performance in
controls across these language groups (Table S9). Significant
differences were seen between the languages when adjusting
for age, sex and education and therefore languagewas used as
a covariate in the analysis.
FP recognition test score correlated with age (rho ¼ .21,
p < .001) (Table S10) and education (rho ¼ .18, p ¼ .005) (Table
S11) within the controls and there was an effect of sex
(p ¼ .006): mean (standard deviation) score overall in controls
was 35.1 (4.6), with a higher score of 35.7 (4.7) in females
(n ¼ 142), compared with 34.3 (4.7) in males (n ¼ 103).
Overall, controls scored between 19 and 40 out of a total
possible score of 40, with cumulative frequency shown in
Table S12. A cut-off score below the 5th percentile is
commonly considered to be abnormal: for the FP recognition
test a score of below 26 would therefore be considered outside
the normal range, with a score of 26 considered borderline
abnormal.
We also compared performance in controls (n¼ 245) across
the FER and FP recognition tests, where there was a significant
but weak correlation: rho ¼ .20, p ¼ .002.
3.2.2. Mutation carriers
All of the three symptomatic mutation carrier groups scored
significantly lower on the FP recognition test compared with
controls (Table 1, Table S13, Fig. 4): C9orf72 22.0 (9.9), GRN 18.7
(12.2) and MAPT 29.2 (7.0), with significantly worse perfor-
mance in the C9orf72 and GRN groups compared with the
MAPT group.
Within each genetic group, scores were significantly lower
in the symptomatic group compared with both the early and
late presymptomatic groups (Table 1, Table S13, Fig. 4).
No significant differences were seen between any of the
presymptomatic groups and controls.3.2.3. Phenotypic analysis
All phenotypic groups [bvFTD (23.1 {10.0}), PPA (21.8 {14.6}) and
an FTD-ALS/ALS group (21.1 {12.1})] were significantly
impaired on the FP recognition test compared with controls,
with no significant differences between any of the clinical
syndromes (Table S14 and Table S15).
3.2.4. Imaging analysis
In the C9orf72mutation carriers, FP recognition test score was
positively correlated with grey matter density in the left su-
perior frontal gyrus, middle temporal gyrus, precuneus and
lingual gyrus, as well as the insula and temporal lobe in the
right hemisphere (Table S16, Fig. 5).
For the GRN mutation carriers, performance on the FP task
was positively correlated with grey matter density in a pre-
dominantly left-sided network of regions including the basal
ganglia, frontal lobe (orbitofrontal cortex, superior and infe-
rior frontal gyri), insula, and temporal lobe (both medial i.e.
amygdala and hippocampus, and other regions).
In the MAPT mutation carriers, there were no significant
correlations when corrected for multiple comparisons. At an
uncorrected p-value <.001, FP recognition test score was
associated with atrophy in the left basal ganglia and left more
than right orbitofrontal cortex mainly.4. Discussion
In this study we have demonstrated that both the FER and FP
recognition tests are able to detect social cognition deficits in
familial forms of FTD during the symptomatic period, but only
the FER test was able to detect presymptomatic deficits
(particularly in the negative emotions of fear and sadness),
specifically within C9orf72 expansion carriers in proximity to
symptom onset. Neural correlates varied across the different
genetic groups with a left hemisphere predominant basal
ganglia-orbitofrontal-insula network implicated across all
three genetic groups on both tasks, except in the C9orf72 group
on the FP recognition test.
Investigation of mutation-negative members of families
within the GENFI cohort has allowed us to study the perfor-
mance of the mini-SEA in a larger healthy control population
than previously, generating normative data across age, sex
and education that can be used in other studies. We show a
significant decline in performance with age with the theory of
mind task consistent with the previous literature (Maylor,
Moulson, Muncer, & Taylor, 2002; Pardini & Nichelli, 2009;
Wang & Su, 2006). Prior studies have also shown an age-
related decline in emotion processing (Mill, Allik, Realo, &
Valk, 2009; Sullivan, Ruffman, & Hutton, 2007, pp. P53eP60;
West et al., 2012), although in our study the correlation was
weak with only a trend to significance (p ¼ .063). A similar
pattern was shown in the correlation with education (worse
score with less years of education) with a weak but significant
correlation on the FP recognition test and only a trend to sig-
nificance in the FER test. Clearer differences were seen when
Fig. 3 e Facial Emotion Recognition test individual emotion subscores, shown as a percentage of the mean control score.
Significant differences from controls are shown with a star at the top of the bar. Differences within each genetic group are
shown with a bracket and star. Differences across genetic groups are not shown.
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Fig. 4 e Faux Pas recognition test scores in each group. Significant differences from controls and within each genetic group
are starred. Differences across genetic groups are not shown.
Fig. 5 e Neural correlates of performance on the Faux Pas recognition test. Results for C9orf72 and GRN groups are shown at
p < .05, corrected for Family Wise Error whilst the results for the MAPT group are shown at p < .001 uncorrected. Results are
shown on a study-specific T1-weighted MRI template in MNI space. Colour bars represent T-values.
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c o r t e x 1 3 3 ( 2 0 2 0 ) 3 8 4e3 9 8 393comparing performance by sex, with females performing
significantly better than males on both tasks as previously
described (Hoffmann, Kessler, Eppel, Rukavina, & Traue, 2010;
Kessels, Montagne, Hendriks, Perrett, & de Haan, 2014; Lee
et al., 2002; Montagne, Kessels, Frigerio, de Haan, & Perrett,
2005). The results highlight the importance of adjusting for
age, sex and education in analyses, particularly for theory of
mind tasks.
Symptomatic mutation carriers in all groups performed
significantly lower than their presymptomatic counterparts
and the controls. This is in line with previous work in sporadic
FTD demonstratingworse performance in FTD comparedwith
controls using both the FER (Bertoux et al., 2014; Diehl-Schmid
et al., 2007; Kumfor, Hazelton, Rushby, Hodges,& Piguet, 2019)
and FP recognition tests (Bertoux, Funkiewiez, O'Callaghan,
Dubois, & Hornberger, 2013; Funkiewiez et al., 2012).
Interestingly, there were no significant differences seen
between phenotypes, with similar performance in the bvFTD,
PPA and FTD-ALS/ALS groups on both the FER and FP recog-
nition tests, and all three phenotypic groups being signifi-
cantly worse than controls on both tasks. This is consistent
with previous reports of social cognition deficits in PPA
(Fittipaldi et al., 2019) and FTD-ALS (Savage et al., 2014) as well
as bvFTD.
Importantly, we also found a decrease in emotion pro-
cessing abilities in the late C9orf72 mutation carriers (those
within 5 years to symptom onset) when compared to controls,
the other late presymptomatic carriers and the early C9orf72
presymptomatic mutation carriers. This deficit was seen
particularly on items of fear and sadness. This finding is
consistent with other smaller studies showing subtle social
cognitive deficits prior to symptom onset in genetic FTD
(Jiskoot et al., 2016, 2018; Cheran et al., 2019). However, in prior
studies, only presymptomatic MAPT and GRN mutation car-
riers have been studied, with deficits in social cognition only
shown in MAPT but not GRN mutation carriers. The differ-
ences from our study (i.e. the lack of deficits shown in MAPT
mutation carriers) may well be accounted for by a difference
in the tests performed (in one study deficits were found in
questionnaires rather than cognitive tests: Cheran et al., 2019),
and the fact that in two of the studies, deficits were only
detected longitudinally, and approaching phenoconversion
(Jiskoot et al., 2016, 2018).
Impairment on tasks of social cognition is likely to involve
breakdown of a number of processes within the brain.
Consistent with this, previous studies of the neural correlates
of social cognition deficits in sporadic FTD have shown an
association of emotional processing difficulties with a variety
of brain regions including frontal (particularly orbitofrontal),
inferior temporal, and insula cortices as well as the amygdala
(reviewed in Kumfor and Piguet, 2012; Couto et al., 2013).
Similarly, theory of mind problems have also been associated
with atrophy within a variety of areas in the brain including
frontal cortex, temporal and insular regions (Adenzato et al.,
2010; Agustus et al., 2015; Bertoux et al., 2014; Guevara et al.,
2015). In our study, orbitofrontal cortex was fairly uniformly
affected across each of the genetic groups e this region is
known to be involved in complex social and emotional
behaviour (Kringelbach, 2004; Rolls, 2004; Beer, John, Scabini,
& Knight, 2006), particularly through a role in stimulus-reinforcement learning and processing of reward. The insula
was similarly affected across the groups in both tasks e this
region is a core hub of the salience network which is involved
in a wide variety of social processes (Menon & Uddin, 2010;
Uddin, Nomi, Hebert-Seropian, Ghaziri, & Boucher, 2017) such
as interoception, the processing of emotional experiences and
the awareness of positive and negative feelings (Craig, 2002),
all required when trying to identify emotions and interpret
social situations. Also previously reported is the association of
the inferior and medial temporal lobe, particularly the
amygdala, with social cognition deficits in FTD, areas known
to be involved in the perception and recognition of facial
emotions e this region was associated with performance on
both the FER test (in C9orf72 andGRNmutation carriers) and FP
recognition tests (in GRN mutation carriers).
A novel finding in this study was the association of the
basal ganglia, particularly the striatum (caudate, putamen and
nucleus accumbens), with impairment of social cognition
across all of the three genetic groups and tests, except for the
C9orf72 FP recognition test performance. This region has pre-
viously been associated with emotion recognition deficits,
particularly negative emotions (Sprengelmeyer et al., 1997;
Calder et al., 2004; Kemp et al., 2013), although in one study of
emotion generation, the basal ganglia was associated with
dysregulation of producing happy emotions (Sturm et al.,
2015). Other studies of sporadic FTD have also shown an as-
sociation of the basal ganglia with performance on implicit
emotion processing tasks (Balconi et al., 2015), and empathy
measures (Rankin et al., 2006; Shdo et al., 2017). Furthermore,
neuroanatomically, the striatum is highly connected with
frontal regions, with fronto-striatal circuits implicated in the
early pathological processes in FTD (Yi et al., 2013; Sobue et al.,
2018) and atrophy in the striatum found across all genetic
subtypes of FTD (Bede et al., 2013; Rohrer et al., 2015; Cash
et al., 2018). This work therefore provides support for the
role of the basal ganglia in social cognitive abilities in genetic
FTD.
A key strength of this study is the large sample size: whilst
familial FTD is a relatively rare condition, by using data
collected as part of GENFI, it allows investigation of a larger
group of individuals with familial FTD including those in the
presymptomatic period. Despite this, some groups remain
with small sample sizes (particularlyMAPTmutation carriers);
the continuation of data collection as part of GENFIwill help to
overcome this problem. A further limitation of the study is the
use of the mean age at onset within a family to estimate the
number of years from likely symptom onset within an indi-
vidual. As shown previously within the GENFI study (Moore
et al., 2020), whilst there is a highly significant correlation
between an individual's age at symptom onset and the mean
age at symptom onset within the family in all three genetic
mutations, the correlations are lower for C9orf72 and GRN
mutation carriers, making the estimate inexact. However,
there are currently no better methods for estimating time
from likely symptom onset at present, with future studies
likely to benefit from the development of more precise mea-
sures of proximity to onset.
Given that structural neuroanatomical changes occur quite
a number of years prior to symptom onset in each of the ge-
netic groups (Rohrer et al., 2015) it may seem surprising that
c o r t e x 1 3 3 ( 2 0 2 0 ) 3 8 4e3 9 8394social cognitive deficits were only shown in one group
(C9orf72) and in one test during the presymptomatic period.
The question then arises as to whether the current tests are
sensitive enough to detect the earliest social cognitive
changes that occur, or whether social cognition deficits would
still be found to occur only very late in the presymptomatic
period or early in the symptomatic period even with other
tasks. Further work is required to tease apart these two pos-
sibilities with the development and testing of novel social
cognitive tasks within such presymptomatic cohorts both
cross-sectionally and particularly longitudinally where one
can identify individuals who phenoconvert. Such studies
would enhance understanding of the timing and progression
of social cognitive changes within genetic FTD.
In summary, this study demonstrates that the FER and FP
recognition tests are able to identify deficits in emotion pro-
cessing and theory of mind in familial cases of FTD across the
three main genetic mutation groups, including during the late
presymptomatic period in C9orf72 mutation carriers.
Furthermore, neuroanatomical regions known to be involved
with social cognition were found to be correlated with per-
formance on the tasks, with the novel finding of basal ganglia
involvement in genetic FTD. This frontal-striatal-insula-
temporal network is highly interconnected and forms part of
a previously described social brain functional network
(Adolphs, 2002; Pessoa, 2017) which allows people to interact
with each other and learn social behaviours so that they can
follow societal norms e factors lost in people in FTD. The FER
and FP recognition tests may prove useful as cognitive
markers in future clinical trials of FTD but further work is
needed to understand the longitudinal change over time, with
further refinement of tasks tomore sensitively detect changes
in the presymptomatic period.CRediT author statement
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